Description: Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation and regenerative medicine. The Company's segments include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places. The Company's drug design methodologies involve chemically linking a base drug to its hydrogen sulfide-releasing molecule. Its lead compound, ATB-346, combines hydrogen sulfide with naproxen, which is a non-steroidal anti-inflammatory drug (NSAID). The Company's other products include ATB-352, which is indicated for the treatment of severe acute pain, and ATB-340 is a Gastrointestinal (GI)-safe derivative of aspirin. The Company also offers regenerative medical devices, which include PentOS (CGX-283), CGX-227, CGX-443 and URIST (CGX-276), all of which target bone regeneration, and are indicated for oral and maxillofacial surgery.
Home Page: www.antibethera.com
ATE Technical Analysis
15 Prince Arthur Avenue
Toronto,
ON
M5R 1B2
Canada
Phone:
416 922 3460
Officers
| Name | Title |
|---|---|
| Mr. Daniel Marcel Legault J.D., L.L.B. | Pres, CEO, Sec. & Director |
| Dr. John Lawrence Wallace M.B.A., M.Sc., MBA, MSc, Ph.D. | Founder & Vice Chair |
| Mr. Alain Wilson M.B.A., MBA | Chief Financial Officer |
| Mr. Scott Curtis C.F.A., M.Eng | Chief Operating Officer |
| Dr. David James Vaughan Ph.D. | Chief Devel. Officer |
| Dr. Joseph Stauffer D.O., M.B.A. | Chief Medical Officer |
| Dr. Ana Stegic | Director of Clinical Operations |
| Ms. Christina Cameron B.B.A. | VP of Investor Relations |
| Mr. Philip Stern | VP of Communications |
Exchange: TO
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5908 |
| Price-to-Sales TTM: | 3.0714 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 37 |